Neisseriaceae Infections Market Report

Global Neisseriaceae Infections Market Size 

The Global Neisseriaceae Infections Market is projected to grow from USD 6.35 billion in 2025 to USD 6.96 billion in 2026 and reach USD 14.43 billion by 2034, registering a CAGR of 9.54% during the forecast period from 2026 to 2034.

MARKET DRIVERS

Bacteria represent the essential class of micro-organisms that play a crucial role in the development of infection of any disease in human beings and animals. They are classified into two types on the basis of gram staining test, viz., gram-positive bacteria and gram-negative bacteria. Neisseria is one of the most important classes of bacteria that form colonies on the mucosal surfaces of animals. Neisseria comprises 11 species, of which two are pathogenic and others are harmless. These belong to the gram-negative class of bacteria because these species show a negative response to the gram test.

As per the U.S. Centers for Disease Control and Prevention (CDC), more than 300,000 new cases of gonorrhea were reported in the U.S. in 2012, an enhancement of around 4% in contrast to 2011. Therefore, such a rising prevalence of infections is an important growth driver of the market. Further, due to extensive R&D practices, a number of drugs and formulations are on the way to entering the market during the forecast period. Some of the important pipeline products include AXD0914, Cribrostatin-6, SM-295291, and SM-369926 amongst numerous others. In addition, owing to the rising incidences of homosexuality and bisexuality, the threat of gonorrhea has also increased. These factors are aided by rising awareness regarding infections and diseases and rising medical expenditure. Due to these, the market is anticipated to grow at a steady rate.

On the other hand, factors such as government austerity, high cost of treatment and R&D, and ignorance towards the symptoms may hamper the growth of the market to a certain extent.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Type of Bacteria Insights

Neisseria contains bacteria such as N. meningitidis, N. gonorrhoeae, N. sicca, N. flava, N. elongata, N. cinerea and others. Out of which, N. gonorrhoeae causes gonorrhea and N. meningitidis causes septicemia and meningitis. Moraxella catarrhalis causes otitis, sinusitis, and pneumonia in adults. Kingella kingae causes urinary, CNS, and respiratory infections.

REGIONAL ANALYSIS

Regionally, North America and Europe are the most prominent markets, owing to the growing prevalence of various Neisseriaceae infections and associated diseases. But still, Asia-Pacific and few countries in the Row region are anticipated to show robust growth in the forecast period, due to rapidly growing prevalence and awareness about the diseases caused because of Neisseriaceae and their chronic effects.

COMPETITIVE LANDSCAPE 

KEY MARKET PLAYERS

A few of the notable companies operating in the Global Neisseriaceae Infections Market profiled in this report are

• Aphios Corporation,
• Basilea Pharmaceuticals Ltd.,
• Pfizer, Inc.,
• GSK plc,
• AstraZeneca plc,
• Adenium Biotech ApS,
• Dainippon Sumitomo Pharma Co., Ltd.,
• Theravance, Inc.,
• Pfizer, Inc.

MARKET SEGMENTATION

This research report on the global neisseriaceae infections market has been segmented and sub-segmented into the following categories.

By Type of Bacteria

• N. Meningitidis     
• N. Gonorrhoeae  
• N. Sicca    
• N. Flava   
• N. Elongata            
• N. Cinerea              
• Others     

By Disease

• Gonorrhea              
• Septicemia              
• Meningitis               
• Sinusitis    
• Otitis          
• Pneumonia             
• CNS            
• Urinary     
• Respiratory Infections 

By Antibacterial Drugs

• Aminoglycosides (Streptomycin)
• B-Lactum Antibiotics (Penicillin)
• Clavulanic Acid (Augmentin)
• Glycopeptides (Vancomycin)
• Polypeptides (Bacitracin)
• Rifamycins (Rifampicin)
• Chloramphenicol
• Tetracycline

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa